MediWound offers catalyst-rich asymmetric upside, pairing an approved burn-care biologic with a potentially disruptive chronic wound therapy—though execution, trial timing, cash burn, and geopolitical risks remain material.
Overview
MediWound is a fully integrated Israeli biopharmaceutical company developing enzymatic, non-surgical tissue repair therapies. Its approved product, NexoBrid, removes burn eschar rapidly while preserving viable tissue and reducing grafting needs, and its late-stage pipeline asset, EscharEx, targets the much larger chronic wound debridement market. Revenues come from product sales, royalties, milestones, and government contracts, including BARDA support. The investment case centers on proprietary bromelain-based technology, partner-led commercialization, institutional adoption in burn care, and EscharEx’s potential to disrupt entrenched chronic wound treatment standards.